tradingkey.logo

Pfizer Inc

PFE

25.940USD

-0.309-1.18%
收盤 03/05, 16:00美東報價延遲15分鐘
147.00B總市值
18.30本益比TTM

Pfizer Inc

25.940

-0.309-1.18%
關於 Pfizer Inc 公司
公司簡介
公司代碼PFE
公司名稱Pfizer Inc
上市日期Jan 17, 1944
成立日期1942
CEODr. Albert Bourla, Ph.D.
員工數量81000
證券類型Ordinary Share
年結日Jan 17
公司地址66 Hudson Boulevard East
城市NEW YORK
上市交易所NYSE Consolidated
國家United States of America
郵編10001-2192
電話12127332323
網址https://www.pfizer.com/
公司代碼PFE
上市日期Jan 17, 1944
成立日期1942
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Albert Bourla, Ph.D.
Dr. Albert Bourla, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
367.99K
+10.69%
Mr. Douglas M. Lankler
Mr. Douglas M. Lankler
Executive Vice President, General Counsel
Executive Vice President, General Counsel
161.03K
+8.26%
Dr. Mikael G. Dolsten, M.D., Ph.D.
Dr. Mikael G. Dolsten, M.D., Ph.D.
Chief Scientific Officer, President - Pfizer Research and Development
Chief Scientific Officer, President - Pfizer Research and Development
128.13K
-26.53%
Ms. Sally Susman
Ms. Sally Susman
Executive Vice President, Chief Corporate Affairs Officer
Executive Vice President, Chief Corporate Affairs Officer
95.93K
+8.23%
Mr. Michael (Ike) Mcdermott
Mr. Michael (Ike) Mcdermott
Executive Vice President, Chief Global Supply Officer
Executive Vice President, Chief Global Supply Officer
70.77K
-0.78%
Mr. Ronald E. Blaylock
Mr. Ronald E. Blaylock
Independent Director
Independent Director
32.45K
+149.66%
Ms. Lidia L. Fonseca, Ph.D.
Ms. Lidia L. Fonseca, Ph.D.
Executive Vice President, Chief Digital and Technology Officer
Executive Vice President, Chief Digital and Technology Officer
30.96K
--
Ms. Payal Sahni
Ms. Payal Sahni
Executive Vice President, Chief People Experience Officer
Executive Vice President, Chief People Experience Officer
24.85K
+6.62%
Dr. Scott Gottlieb, M.D.
Dr. Scott Gottlieb, M.D.
Independent Director
Independent Director
10.00K
+11.11%
Mr. James Clifton (Jim) Smith
Mr. James Clifton (Jim) Smith
Independent Director
Independent Director
3.54K
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Albert Bourla, Ph.D.
Dr. Albert Bourla, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
367.99K
+10.69%
Mr. Douglas M. Lankler
Mr. Douglas M. Lankler
Executive Vice President, General Counsel
Executive Vice President, General Counsel
161.03K
+8.26%
Dr. Mikael G. Dolsten, M.D., Ph.D.
Dr. Mikael G. Dolsten, M.D., Ph.D.
Chief Scientific Officer, President - Pfizer Research and Development
Chief Scientific Officer, President - Pfizer Research and Development
128.13K
-26.53%
Ms. Sally Susman
Ms. Sally Susman
Executive Vice President, Chief Corporate Affairs Officer
Executive Vice President, Chief Corporate Affairs Officer
95.93K
+8.23%
Mr. Michael (Ike) Mcdermott
Mr. Michael (Ike) Mcdermott
Executive Vice President, Chief Global Supply Officer
Executive Vice President, Chief Global Supply Officer
70.77K
-0.78%
Mr. Ronald E. Blaylock
Mr. Ronald E. Blaylock
Independent Director
Independent Director
32.45K
+149.66%
收入明細
單位: USD更新時間: 3月5日 週三
單位: USD更新時間: 3月5日 週三
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
業務USD
名稱
營收
佔比
Eliquis alliance revenues and direct sales
7.36B
11.57%
Prevnar family
6.41B
10.07%
Paxlovid
5.71B
8.98%
Vyndaqel family
5.45B
8.56%
Comirnaty
5.35B
8.41%
Other
33.33B
52.38%
地區USD
名稱
營收
佔比
United States
38.69B
60.80%
Developed Markets
16.05B
25.23%
Emerging Markets
8.87B
13.95%
業務
地區
業務USD
名稱
營收
佔比
Eliquis alliance revenues and direct sales
7.36B
11.57%
Prevnar family
6.41B
10.07%
Paxlovid
5.71B
8.98%
Vyndaqel family
5.45B
8.56%
Comirnaty
5.35B
8.41%
Other
33.33B
52.38%
股東統計
更新時間: 2月21日 週五
更新時間: 2月21日 週五
持股股東
股東類型
持股股東
股東統計
佔比
The Vanguard Group, Inc.
9.10%
State Street Global Advisors (US)
5.12%
BlackRock Institutional Trust Company, N.A.
4.93%
Charles Schwab Investment Management, Inc.
2.74%
Wellington Management Company, LLP
2.47%
Other
75.62%
持股股東
股東統計
佔比
The Vanguard Group, Inc.
9.10%
State Street Global Advisors (US)
5.12%
BlackRock Institutional Trust Company, N.A.
4.93%
Charles Schwab Investment Management, Inc.
2.74%
Wellington Management Company, LLP
2.47%
Other
75.62%
股東類型
股東統計
佔比
Investment Advisor/Hedge Fund
30.95%
Investment Advisor
24.86%
Research Firm
2.99%
Pension Fund
2.13%
Bank and Trust
1.86%
Hedge Fund
1.72%
Sovereign Wealth Fund
1.64%
Insurance Company
1.17%
Holding Company
0.20%
Other
32.43%
機構持股
更新時間: 2月21日 週五
更新時間: 2月21日 週五
報告期間
機構數
持股數
持股佔比
持股變動
2025Q1
4913
3.83B
67.69%
-85.85M
2024Q4
5153
3.83B
67.74%
-83.25M
2024Q3
5005
3.85B
67.99%
-51.77M
2024Q2
5026
3.83B
67.75%
-120.77M
2024Q1
5032
3.89B
68.71%
-120.38M
2023Q4
5089
3.96B
70.25%
-96.67M
2023Q3
4952
4.00B
70.89%
-71.80M
2023Q2
4962
4.01B
71.16%
-62.34M
2023Q1
4947
4.02B
71.28%
-30.98M
2022Q4
4927
4.00B
71.39%
-30.89M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
The Vanguard Group, Inc.
515.97M
9.1%
+2.33M
+0.45%
Dec 31, 2024
State Street Global Advisors (US)
290.48M
5.12%
+23.75K
+0.00%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
279.54M
4.93%
+4.28M
+1.55%
Dec 31, 2024
Charles Schwab Investment Management, Inc.
155.45M
2.74%
+25.31M
+19.45%
Dec 31, 2024
Wellington Management Company, LLP
139.99M
2.47%
-23.73M
-14.49%
Dec 31, 2024
Geode Capital Management, L.L.C.
120.58M
2.12%
+2.92M
+2.48%
Dec 31, 2024
Norges Bank Investment Management (NBIM)
87.78M
1.54%
+3.82M
+4.55%
Dec 31, 2024
MFS Investment Management
74.21M
1.3%
+5.44M
+7.92%
Dec 31, 2024
State Farm Insurance Companies
54.50M
0.96%
--
--
Dec 31, 2024
BlackRock Asset Management Ireland Limited
45.95M
0.81%
+2.00M
+4.55%
Dec 31, 2024
查看更多
持股ETF
更新時間: 13 小時前
更新時間: 13 小時前
機構名稱
佔比
First Trust Morningstar Dividend Leaders Index Fund
7.28%
First Trust NASDAQ Pharmaceuticals ETF
6.22%
Amplify Weight Loss Drug & Treatment ETF
5.32%
NYLI Healthy Hearts ETF
5.04%
iShares U.S. Pharmaceuticals ETF
4.84%
Invesco Pharmaceuticals ETF
4.84%
WBI BullBear Yield 3000 ETF
4.72%
ProShares Smart Materials ETF
4.59%
Schwab U.S. Dividend Equity ETF
4.48%
VanEck Pharmaceutical ETF
4.41%
查看更多
First Trust Morningstar Dividend Leaders Index Fund
佔比7.28%
First Trust NASDAQ Pharmaceuticals ETF
佔比6.22%
Amplify Weight Loss Drug & Treatment ETF
佔比5.32%
NYLI Healthy Hearts ETF
佔比5.04%
iShares U.S. Pharmaceuticals ETF
佔比4.84%
Invesco Pharmaceuticals ETF
佔比4.84%
WBI BullBear Yield 3000 ETF
佔比4.72%
ProShares Smart Materials ETF
佔比4.59%
Schwab U.S. Dividend Equity ETF
佔比4.48%
VanEck Pharmaceutical ETF
佔比4.41%
分紅派息
近5年累計派現 44.91B 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
Dec 12, 2024
PFE.NB Interim Cash Dividend of gross USD 0.43 paid on Mar 07, 2025 going ex on Jan 24, 2025
Jan 24, 2025
Mar 07, 2025
Jan 24, 2025
Oct 09, 2024
PFE.NB Final Cash Dividend of gross USD 0.42 paid on Dec 02, 2024 going ex on Nov 08, 2024
Nov 08, 2024
Dec 02, 2024
Nov 08, 2024
Jun 26, 2024
PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Sep 03, 2024 going ex on Jul 26, 2024
Jul 26, 2024
Sep 03, 2024
Jul 26, 2024
Apr 24, 2024
PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Jun 14, 2024 going ex on May 09, 2024
May 10, 2024
Jun 14, 2024
May 09, 2024
Dec 14, 2023
PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Mar 01, 2024 going ex on Jan 25, 2024
Jan 26, 2024
Mar 01, 2024
Jan 25, 2024
Oct 04, 2023
PFE.NB Final Cash Dividend of gross USD 0.41 paid on Dec 04, 2023 going ex on Nov 09, 2023
Nov 10, 2023
Dec 04, 2023
Nov 09, 2023
Jun 22, 2023
PFE.NB Interim Cash Dividend of gross USD 0.41 paid on Sep 05, 2023 going ex on Jul 27, 2023
Jul 28, 2023
Sep 05, 2023
Jul 27, 2023
Apr 26, 2023
PFE.NB Interim Cash Dividend of gross USD 0.41 paid on Jun 09, 2023 going ex on May 11, 2023
May 12, 2023
Jun 09, 2023
May 11, 2023
Dec 09, 2022
PFE.NB Interim Cash Dividend of gross USD 0.41 paid on Mar 03, 2023 going ex on Jan 26, 2023
Jan 27, 2023
Mar 03, 2023
Jan 26, 2023
Sep 22, 2022
PFE.NB Final Cash Dividend of gross USD 0.4 paid on Dec 05, 2022 going ex on Nov 03, 2022
Nov 04, 2022
Dec 05, 2022
Nov 03, 2022
查看更多
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
tradingkey.logo
tradingkey.logo
日內數據由路孚特(Refinitiv)提供,並受使用條款約束。歷史及當前收盤數據均由路孚特提供。所有報價均以當地交易所時間為準。美股報價的即時最後成交數據僅反映透過納斯達克報告的交易。日內數據延遲至少15分鐘或遵循交易所要求。
* 參考、分析和交易策略由提供商Trading Central提供,觀點基於分析師的獨立評估和判斷,未考慮投資者的投資目標和財務狀況。
風險提示:我們的網站和行動應用程式僅提供關於某些投資產品的一般資訊。Finsights 不提供財務建議或對任何投資產品的推薦,且提供此類資訊不應被解釋為 Finsights 提供財務建議或推薦。
投資產品存在重大投資風險,包括可能損失投資的本金,且可能並不適合所有人。投資產品的過去表現並不代表其未來表現。
Finsights 可能允許第三方廣告商或關聯公司在我們的網站或行動應用程式的任何部分放置或投放廣告,並可能根據您與廣告的互動情況獲得報酬。
© 版權所有: FINSIGHTS MEDIA PTE. LTD. 版權所有